New ‘Breakthrough’ Therapy for Non-CF Bronchiectasis
The US FDA recently granted Breakthrough Therapy Designation to a novel inhaled therapy called CMS I-neb, which is designed to treat non-CF bronchiectasis.
The US FDA recently granted Breakthrough Therapy Designation to a novel inhaled therapy called CMS I-neb, which is designed to treat non-CF bronchiectasis.
A new study sheds light on risk factors for bronchiectasis in patients with aspirin-exacerbated respiratory disease (AERD).
Mutations in genes linked to other lung diseases, specifically cystic fibrosis and primary ciliary...